Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | June 2010 |
Effects of 19-Nor-1α-Dihydroxyvitamin D2 (Paricalcitol) Versus Placebo on Oxidative Stress and Vascular Reactivity in CKD Patients
This research is studying how Vitamin D may affect blood vessels reaction to stress and
blood levels of substances that may increase blockages in the blood vessels in chronic
kidney disease (CKD) patients. Blood vessel health is worsened in CKD and some studies have
shown that Vitamin D improves blood vessel health. The type of Vitamin D being used in this
study (paricalcitol) is Food and Drug Administration (FDA) approved to treat high
parathyroid hormone levels. The purpose of this study is to find out if paricalcitol has
other benefits beyond its ability to lower parathyroid hormone levels such as improving the
blood vessels reaction to stress and decreasing blood levels of substances that may increase
blockages in the blood vessels.
We found this trial at
1
site
Click here to add this to my saved trials
